Equity Profile

ELVN

Enliven Therapeutics, Inc.

Health CarePharmaceuticals$2.1B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to improve patient outcomes. As part of the health care sector, its advancements could significantly impact treatment options in various diseases, making it a company to watch in the evolving pharmaceutical landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In Q1-2026, Enliven reported an EPS of -$0.38, beating estimates by 13.64%. However, the stock fell by 2.21% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating a volatile reaction to the upcoming earnings report, with a significant implied move of around 39%. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Enliven can continue its trend of beating EPS estimates, it may signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

The EPS figure will be a critical measure of the company's profitability and could heavily influence investor sentiment.

What is the company's outlook on revenue growth for the upcoming quarters?

Revenue growth is essential for assessing the company's future potential and market position, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Enliven's ability to deliver a positive surprise based on its recent trend of beating EPS estimates.

Supporting Evidence

Enliven has a 75% EPS beat rate over the last eight quarters, indicating a strong potential for positive surprises.

The significant implied move of 39% suggests that traders are anticipating volatility, which could favor a positive outcome.

Key Risk

If the EPS comes in above -$0.30, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will set the tone for investor confidence and future growth prospects.

Bull Confirmed If

A positive EPS surprise of more than 15% would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS miss of more than 10% would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±39.0%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$238,352.42

5,000 sh

1 insider

Net

$238,352.42

Net selling

Most Active Insiders· 3 open-market trades

CHIEF MEDICAL OFFICERCollins Helen Louise
$238,352.42

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests a modest positive reaction, averaging around +3.1% on the first day.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may experience a muted reaction as investors reassess future growth.

Miss

A miss could lead to a decline, with historical averages indicating a potential drop of around -1.62% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on future revenue expectations and growth strategies.
5Any changes to the company's long-term strategic goals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In Q1-2026, Enliven reported an EPS of -$0.38, beating estimates by 13.64%. However, the stock fell by 2.21% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating a volatile reaction to the upcoming earnings report, with a significant implied move of around 39%. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Enliven can continue its trend of beating EPS estimates, it may signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

The EPS figure will be a critical measure of the company's profitability and could heavily influence investor sentiment.

What is the company's outlook on revenue growth for the upcoming quarters?

Revenue growth is essential for assessing the company's future potential and market position, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Enliven's ability to deliver a positive surprise based on its recent trend of beating EPS estimates.

Supporting Evidence

Enliven has a 75% EPS beat rate over the last eight quarters, indicating a strong potential for positive surprises.

The significant implied move of 39% suggests that traders are anticipating volatility, which could favor a positive outcome.

Key Risk

If the EPS comes in above -$0.30, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will set the tone for investor confidence and future growth prospects.

Bull Confirmed If

A positive EPS surprise of more than 15% would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS miss of more than 10% would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±39.0%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$238,352.42

5,000 sh

1 insider

Net

$238,352.42

Net selling

Most Active Insiders· 3 open-market trades

CHIEF MEDICAL OFFICERCollins Helen Louise
$238,352.42

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests a modest positive reaction, averaging around +3.1% on the first day.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may experience a muted reaction as investors reassess future growth.

Miss

A miss could lead to a decline, with historical averages indicating a potential drop of around -1.62% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on market conditions and competitive landscape.
3Insights into cost management and operational efficiencies.
4Guidance on future revenue expectations and growth strategies.
5Any changes to the company's long-term strategic goals.